Diabetes Mellitus in Cancer Patients Treated with Combination Interleukin 2 and α-Interferon
- 1 January 1995
- journal article
- case report
- Published by Mary Ann Liebert Inc in Cancer Biotherapy
- Vol. 10 (1) , 45-51
- https://doi.org/10.1089/cbr.1995.10.45
Abstract
Diabetes mellitus is thought to be an autoimmune disease caused by destruction of beta cells in pancreatic islets. Insulin resistance in the peripheral tissues may also play a role. Both interleukin 2 (IL-2) and alpha interferon can enhance immune function by stimulating formation of cytolytic T cells and/or antigen expression on both normal and tumor cells. This report describes three patients with advanced malignancy who were treated with combination IL-2 and α interferon who had the onset or worsening of diabetes mellitus. One patient died as a result. There is evidence that interferon can increase insulin resistance and it is likely that both agents can initiate or enhance an ongoing autoimmune process. Physicians using this combination of drugs should be aware of this potential serious toxicity.Keywords
This publication has 18 references indexed in Scilit:
- Thyroid Function Abnormalities Associated with the Chronic Outpatient Administration of Recombinant Interleukin-2 and Recombinant Interferon-AlphaJournal of Immunotherapy, 1991
- Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-α)Clinical and Experimental Immunology, 1990
- Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignanciesThe Lancet, 1990
- A Randomized Trial of Intensive Insulin Therapy in Newly Diagnosed Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- The Role of Interferon in Cancer Therapy: A Current PerspectiveCA: A Cancer Journal for Clinicians, 1988
- Hypothyroidism after Treatment with Interleukin-2 and Lymphokine-Activated Killer CellsNew England Journal of Medicine, 1988
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trialsJournal of Immunological Methods, 1987
- Thyroid Autoimmunity in Patients on Long Term Therapy with Leukocyte-Derived Interferon*Journal of Clinical Endocrinology & Metabolism, 1986
- In Situ Characterization of Autoimmune Phenomena and Expression of HLA Molecules in the Pancreas in Diabetic InsulitisNew England Journal of Medicine, 1985
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982